ROCK Inhibitor–Based
Innovative Drugs for Degenerative Diseases

SCROLL DOWN

News

2026-05-18

Bichedam Completes Phase I Clinical Trial of BCD101, Demonstrating the Feasibility of Oral Puerarin Administration

2026-04-09

Saengmaeksan-gagambang Demonstrates Significant Improvement in Arterial Stiffness, Highlighting Its Potential as a Novel

[The Korean Medicine Newspaper] Clinical research demonstrating that Modified Saengmaeksan (BCD101) has positive effects on improving arterial stiffness in middle-aged women has ...

2026-04-08

Bichedam Launches Human Clinical Trial for ‘G Care’ to Verify Its Effectiveness in Improving Nocturnal Leg Cramps

Bichedam, a company specializing in natural product-based pharmaceuticals, announced on the 8th that it has initiated a human clinical study to evaluate the efficacy and safety...

2025-12-11

Gyeongsangbuk-do & Gyeongbuk TP Hold 2025 Gyeongbuk Regional Investment Forum

Gyeongsangbuk-do Province and Gyeongbuk Technopark (President Ha In-seong) held the 2025 Gyeongbuk Regional Investment Forum on the 10th at Laonjena Hotel ...

Saengmaeksan-gagambang Demonstrates Significant Improvement in Arterial Stiffness, Highlighting Its Potential as a Novel

2026-04-09

Bichedam Launches Human Clinical Trial for ‘G Care’ to Verify Its Effectiveness in Improving Nocturnal Leg Cramps

2026-04-08

Gyeongsangbuk-do & Gyeongbuk TP Hold 2025 Gyeongbuk Regional Investment Forum

2025-12-11

Bichedam Completes Phase I Clinical Trial of BCD101, Demonstrating the Feasibility of Oral Puerarin Administration

2026-05-18

COMPANY

BICHEDAM, a Korean biopharma developing natural, herbal-based treatments for hypertension, dementia, and other age-related diseases.

HISTORY

BICHEDAM’s ongoing growth, efforts, and plans since its founding in April 2022.

PARTNERS

BICHEDAM’s ongoing growth, efforts, and plans since its founding in April 2022.

Pipeline